Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DNA and Histone Methyltransferase Inhibitors Cooperate to Increase Viral Mimicry in Ovarian Cancer Cells

ABSTRACT: DNA and Histone Methyltransferase Inhibitors Cooperate to Increase Viral Mimicry in Ovarian Cancer Cells

PROVIDER: PRJNA422873 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7470310.fastq.gz	Fastqsanger.gz
	SRR7470320.fastq.gz	Fastqsanger.gz
	SRR7470330.fastq.gz	Fastqsanger.gz
	SRR7470340.fastq.gz	Fastqsanger.gz
	SRR7470311.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

Nicotinamide N-methyltransferase promotes metastatic colonisation via cancer cell stromal mimicry

Project description:Nicotinamide N-methyltransferase promotes metastatic colonisation via cancer cell stromal mimicry.

2023-04-24 | PXD027964 | Pride

DNA and Histone Methyltransferase Inhibitors Cooperate to Increase Viral Mimicry in Ovarian Cancer Cells

Project description:Total RNA sequenceing method was used to compare the differential expression of genes in A2780, CAOV3, PEO14, and OAW42 cells with G9Ai, 5-aza-CdR and combination treatment compared to untreated cells

2018-09-30 | GSE108223 | GEO

Histone PTM analysis in breast cancer cells treated with methyltransferase inhibitors

Project description:Histone PTM analysis were analyzed in breast cancer cells treated with methyltransferase inhibitors.

2025-08-01 | PXD064421 | Pride

Protein arginine methyltransferase 5 mediates the increase in interferon stimulated genes during replication stress

Project description:Replication stress (RS) is a hallmark of cancer and is defined as the perturbation of DNA replication that results in stalled or collapsed DNA replication forks. Chemotherapeutic drugs exploit this phenomenon by enhancing the RS, resulting in cell death. Protein arginine methyltransferase 5 (PRMT5) is responsible for post-translational symmetric dimethylarginine (SDMA) modification. This modification is important for regulating RS. PRMT5 is upregulated in several malignancies and therefore inhibitors have been developed. To understand the consequences of PRMT5 inhibition, we investigated its role in replication stress response. Employing the RS inducer hydroxyurea (HU) and the PRMT5 inhibitor GSK591, we discovered a PRMT5-mediated increase in SDMA during RS. Furthermore, we observed that RS resulted in a PRMT5-dependent transcriptional increase in interferon-stimulated genes (ISGs). Therefore, we demonstrated a previously unreported role for PRMT5-mediated SDMA in the context of RS.

2024-08-30 | GSE236930 | GEO

Priming with DNMT inhibitors potentiates PD-1 immunotherapy by triggering viral mimicry in relapsed/refractory NK/T-cell lymphoma

Project description:Anti-PD-1 immunotherapy has demonstrated significant anti-tumor efficacy in treating relapsed or refractory natural killer/T cell lymphoma (R/R NKTL). However, both intrinsic and acquired resistance remain a substantial challenge. DNA hypermethylation serves as a critical epigenetic modifier influencing anti-tumor immunity in NKTL. Here, we evaluate the efficacy and safety of combining DNA methyltransferase (DNMT) inhibitors with anti-PD-1 monoclonal antibody (mAb) as salvage therapy in 21 patients with R/R NKTL who had previously failed frontline immunotherapy. This combination therapy achieved an objective response rate (ORR) of 66.7% (14/21), with a complete response (CR) rate of 47.6% (10/21), and a 2-year overall survival (OS) rate of 50.2%. To investigate the mechanisms underlying the therapeutic efficacy of this combination, we established a preclinical xenograft model of acquired resistance to anti-PD-1 therapy. Our findings revealed that resistance to anti-PD-1 treatment was characterized by the absence of CD8+ T-cell infiltration and the inactivation of interferon pathways. In contrast, DNMT inhibitors restored CD8+ T-cell infiltration, and sensitized tumors to anti-PD-1 therapy. Mechanistically, DNMT inhibitors induced DNA demethylation of endogenous retroviral elements (ERVs), leading to the upregulation of endogenous nucleic acid expression and the activation of a viral mimicry response. This response subsequently triggered the type I interferon pathway, thereby enhancing anti-tumor immunity in both murine and human T-cell lymphoma models. Collectively, our study highlights the potential of DNMT inhibitors in restoring tumor sensitivity to anti-PD-1 therapy and provides compelling evidence for combining DNMT inhibitors with anti-PD-1 mAb as a promising therapeutic strategy for R/R NKTL.

2025-08-13 | GSE292179 | GEO

Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving Calcium-Calcineurin-NFAT signaling [EPIC]

Project description:DNA methyltransferase inhibitors (DNMTi) are FDA-approved for various hematological malignancies but have limited efficacy in solid tumors. DNA hypomethylation with these drugs is associated with elevated lysine 27 tri-methylation on histone H3 (H3K27me3). We hypothesized that this EZH2-dependent repressive mark limits the full potential of DNMTi. Here, we show in cell line and tumoroid models of colorectal cancer, that low-dose DNMTi sensitizes cells to selective EZH2 inhibitors (EZH2i) that have limited single agent toxicity, and that EZH2i enhances DNMTi-driven molecular and therapeutic effects. Through integrative epigenomic analyses, we reveal that DNMTi induces H3K27me3 accumulation at genomic regions poised with EZH2. Unexpectedly, combined treatment alters the epigenome landscape to promote transcriptional upregulation of the Calcium-Calcineurin-NFAT signaling pathway. Blocking this pathway limits the transcriptional activating effects of the drug combination, including expression of transposable elements and innate immune response genes within a viral defense pathway. Consistently, we demonstrate positive correlations between DNMTi- and viral infection-associated transcription profiles and Calcium signal activation in colon cancer patient samples. Collectively, our study demonstrates that compensatory EZH2 activity following DNA hypomethylation presents a barrier to the therapeutic action of DNMTi in colon cancer, reveals a new application of EZH2i beyond cancers associated with PRC2 hyperactivity, and links Calcium-Calcineurin-NFAT signaling to epigenetic therapy-induced viral mimicry.

2024-02-26 | GSE237553 | GEO

Retinoids and EZH2 inhibitors cooperate to orchestrate cytotoxic effects on bladder cancer cells

Project description:Retinoids and EZH2 inhibitors cooperate to orchestrate cytotoxic effects on bladder cancer cells

| PRJNA952561 | ENA

Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving Calcium-Calcineurin-NFAT signaling [siQ-ChIP]

2024-02-26 | GSE236897 | GEO

Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving Calcium-Calcineurin-NFAT signaling [RNA-seq]

2024-02-26 | GSE236896 | GEO

Select EZH2 inhibitors enhance the viral mimicry effects of DNMT inhibition through a mechanism involving Calcium-Calcineurin-NFAT signaling [EM-seq]

2024-02-26 | GSE237662 | GEO